Martin Cegan1, Katarina Kolostova2, Rafal Matkowski3, Marek Broul4, Jan Schraml4, Marek Fiutowski5, Vladimir Bobek6. 1. Department of Pathology, Masaryk's Hospital in Usti Nad Labem Krajska Zdravotni a.s., Socialni Pece 3316, 12A40113 Usti Nad Labem, Czech Republic. 2. Department of Laboratory Genetics University Hospital Kralovske Vinohrady Srobarova 50, 100 97 Prague, Czech Republic. 3. Department of Oncology and Division of Oncological Surgery, Wroclaw Medical University ul. Pasteura 1, 50-367 Wrocław, Poland ; Lower Silesian Oncology Centre Plac Hirszfelda 12, 53-413 Wrocław, Poland. 4. Department of Urology and Center of Robotic Surgery, Masaryk's Hospital in Usti Nad Labem Krajska Zdravotni a.s., Socialni Pece 3316, 12A40113 Usti Nad Labem, Czech Republic. 5. Department of Urology, Regional Specialistic Hospital ul. Kamienskiego 73a, 51-318 Wroclaw, Poland. 6. Department of Laboratory Genetics University Hospital Kralovske Vinohrady Srobarova 50, 100 97 Prague, Czech Republic ; Department of Histology and Embryology, Wroclaw Medical University Chalubinskiego 6a, 50-368 Wroclaw, Poland ; Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol 105 00 Prague, Czech Republic.
Abstract
OBJECTIVE: Approximately one third of patients diagnosed with muscle-invasive urinary bladder cancer (UBC) have undetected metastases at the time of treatment of the primary tumor. Currently there are no reliable specific serum markers for monitoring and evaluating risk profiles of urothelial cancers. Several studies suggest that detection of circulating tumor cells (CTCs) may correlate with the disease status and prognosis at baseline and early in the treatment of cancers. In this study a new way of isolation and in vitro cultivation of CTCs of urinary bladder cancer was introduced. MATERIALS AND METHODS: Peripheral blood (PB) samples from 53 patients who had undergone urological procedure were evaluated using the MetaCell device (MetaCell s.r.o., Ostrava, Czech Republic). The patients enrolled in the study were both oncological patients with UBC and non-oncological patients with inflammation (14 patients). The sensitivity and quantification of CTCs were evaluated. The separated CTCs were cultured in vitro. RESULTS: 39 patients with confirmed UBC were enrolled in the study. CTCs were detected in 25 (64%) patients, and most of these patients had between 6 and 10 cells. The separated CTCs were successfully cultured in vitro. CONCLUSION: CTCs were detected in a higher percentage of patients than in other studies. This paper describes the first successful culturing of human UBC cells. The MetaCell approach used in this study enabled the capture of viable intact virgin CTCs (virgin CTC) suitable for next in vitro culturing, single cell analysis or drug testing.
OBJECTIVE: Approximately one third of patients diagnosed with muscle-invasive urinary bladder cancer (UBC) have undetected metastases at the time of treatment of the primary tumor. Currently there are no reliable specific serum markers for monitoring and evaluating risk profiles of urothelial cancers. Several studies suggest that detection of circulating tumor cells (CTCs) may correlate with the disease status and prognosis at baseline and early in the treatment of cancers. In this study a new way of isolation and in vitro cultivation of CTCs of urinary bladder cancer was introduced. MATERIALS AND METHODS: Peripheral blood (PB) samples from 53 patients who had undergone urological procedure were evaluated using the MetaCell device (MetaCell s.r.o., Ostrava, Czech Republic). The patients enrolled in the study were both oncological patients with UBC and non-oncological patients with inflammation (14 patients). The sensitivity and quantification of CTCs were evaluated. The separated CTCs were cultured in vitro. RESULTS: 39 patients with confirmed UBC were enrolled in the study. CTCs were detected in 25 (64%) patients, and most of these patients had between 6 and 10 cells. The separated CTCs were successfully cultured in vitro. CONCLUSION: CTCs were detected in a higher percentage of patients than in other studies. This paper describes the first successful culturing of human UBC cells. The MetaCell approach used in this study enabled the capture of viable intact virgin CTCs (virgin CTC) suitable for next in vitro culturing, single cell analysis or drug testing.
Authors: Shahrokh F Shariat; Ganesh S Palapattu; Pierre I Karakiewicz; Craig G Rogers; Amnon Vazina; Patrick J Bastian; Mark P Schoenberg; Seth P Lerner; Arthur I Sagalowsky; Yair Lotan Journal: Eur Urol Date: 2006-06-08 Impact factor: 20.096
Authors: Thomas W Flaig; Shandra Wilson; Adrie van Bokhoven; Marileila Varella-Garcia; Pamela Wolfe; Paul Maroni; E Erin Genova; Diana Morales; M Scott Lucia Journal: Urology Date: 2011-08-02 Impact factor: 2.649
Authors: Derya Tilki; Maximilian Burger; Guido Dalbagni; H Barton Grossman; Oliver W Hakenberg; Juan Palou; Oliver Reich; Morgan Rouprêt; Shahrokh F Shariat; Alexandre R Zlotta Journal: Eur Urol Date: 2011-06-12 Impact factor: 20.096
Authors: Michael Rink; Felix K H Chun; Sarah Minner; Martin Friedrich; Oliver Mauermann; Hans Heinzer; Hartwig Huland; Margit Fisch; Klaus Pantel; Sabine Riethdorf Journal: BJU Int Date: 2010-08-24 Impact factor: 5.588
Authors: Alexander Karl; Peter R Carroll; Jürgen E Gschwend; Ruth Knüchel; Francesco Montorsi; Christian G Stief; Urs E Studer Journal: Eur Urol Date: 2009-01-13 Impact factor: 20.096
Authors: Katarina Kolostova; Eliska Pospisilova; Vladimira Pavlickova; Robert Bartos; Martin Sames; Ireneusz Pawlak; Vladimir Bobek Journal: Am J Transl Res Date: 2021-05-15 Impact factor: 4.060
Authors: Katarina Kolostova; Rafał Matkowski; Marcin Jędryka; Katarzyna Soter; Martin Cegan; Michael Pinkas; Anna Jakabova; Jiri Pavlasek; Jan Spicka; Vladimir Bobek Journal: Am J Cancer Res Date: 2015-10-15 Impact factor: 6.166
Authors: Katarina Kolostova; Adam Rzechonek; Jan Schützner; Robert Grill; Robert Lischke; Pavel Hladik; Jan Simonek; Vladimir Bobek Journal: In Vivo Date: 2017 Nov-Dec Impact factor: 2.155